SLNCF — Silence Therapeutics plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1479615 ·
United Kingdom
Last close
$4.00
Market Cap
$745.85M
52W High
$5.99
52W Low
$1.06
ADV30
90
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -13,865,000 | -12,268,000 | 106,412,000 | 72,054,000 | 67,941,000 |
| Mar 2026 | 422,000 | 411,000 | -15,737,000 | -14,957,000 | 115,123,000 | 5,657,000 | 65,721,000 |
| Dec 2025 | 34,000 | 22,000 | -12,461,000 | -11,770,000 | 131,442,000 | 11,277,000 | 69,138,000 |
| Sep 2025 | 159,000 | 95,000 | -26,244,000 | -20,958,000 | 146,790,000 | 82,031,000 | 72,727,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-65,565,000
Investing CF
$6,389,000
Financing CF
$1,000
CapEx
$-110,768
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.65
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-577,526,000
Inventory
—
Receivables
$22,216,000
ST Investments
$64,421,000
EBIT TTM
$-77,081,000
Pretax Income TTM
$-75,028,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$615,000
EBITDA
$-63,942,000
Free Cash Flow
$-23,567,624
Enterprise Value
$495,018,144
Total Cash
$72,054,000
Total Debt
$112,000
Shares Out
186,462,258
Trailing EPS
$-0.43
Book Value
$0.27
ROE
-90.4%
ROA
-29.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 559,000 | -89,753,000 | -88,612,000 | 131,442,000 | 69,138,000 | 62,304,000 | -62,271,000 |
| Dec 2024 | 43,258,000 | -63,319,000 | -45,309,000 | 202,635,000 | 68,612,000 | 134,023,000 | -67,640,000 |
| Dec 2023 | 31,643,000 | -64,383,000 | -54,228,000 | 119,448,000 | 97,455,000 | 21,993,000 | -49,462,000 |
| Dec 2022 | 21,655,000 | -61,040,000 | -50,334,000 | 130,096,453 | 103,384,928 | 26,711,525 | -57,044,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.38
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| WVE | Wave Life Sciences, Inc. | $744.84M | $3.78 | — |
| PHAR | Pharming Group N.V. | $740.34M | $10.46 | — |
| ACRS | Aclaris Therapeutics, Inc. | $758.07M | $5.15 | — |
| DSGN | Design Therapeutics, Inc. | $758.49M | $12.12 | — |
| IVEVF | Inventiva S.A. | $760.63M | $3.22 | — |
News headlines (Yahoo Finance, 1h cache)
Silence Therapeutics to Participate in Three September Investor Conferences
2026-09-02 12:00 · Yahoo
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
2026-08-14 20:55 · Yahoo
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
2026-08-12 03:20 · Yahoo
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
2026-08-11 05:01 · Yahoo
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
2026-08-10 20:01 · Yahoo
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
2026-08-10 11:30 · Yahoo
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
2026-08-10 11:15 · Yahoo
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
2026-08-09 21:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Higher Monday
2026-03-16 15:22 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
2026-03-10 15:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.